Refine your search
Collections
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Dawood, Ali Adel
- Did the SARS-CoV-2 Come from Wild, Mutagenic or Artificial Type? Complete Genome Analysis
Abstract Views :77 |
PDF Views:0
Authors
Affiliations
1 Department of Anatomy, College of Medicine, University of Mosul, Mosul, IQ
2 Department of Biophysics, College of Science, University of Mosul, Mosul, IQ
3 Department of Biology, College of Science, University of Mosul, Mosul, IQ
1 Department of Anatomy, College of Medicine, University of Mosul, Mosul, IQ
2 Department of Biophysics, College of Science, University of Mosul, Mosul, IQ
3 Department of Biology, College of Science, University of Mosul, Mosul, IQ
Source
Research Journal of Science and Technology, Vol 14, No 1 (2022), Pagination: 21-29Abstract
Questions that come to mind about the true genetic origin of the novel coronavirus and its direct source. As it is likely that these questions will be answered through aspects of the relationship between science and intelligence, the results of which will converge together in the end to some evidence. Materials and methods: The 29 complete coronavirus and HIV genomes were collected from various countries at random and conducted various bioinformatics instruments in order to find connections between viral sequences from various sources. Results: The closest similarity between the SARS-CoV-2 genomes approximately (99.98%). The small difference between genome sequences is considered as weak mutations occur even at the present time. This study revealed that the novel coronavirus had a structure identical to the HIV virus which it reached approximately 46.33%. Conclusions: It is not possible for the SARS-CoV-2 to be related to HIV through mutation, manipulation, or laboratory artificial. Laboratory mutation occurred in the Wuhan lab and led to the outbreak of the epidemic, deliberately or accidentally, and this will be determined later.Keywords
COVID-19, Origin, NCBI, ViPR, Bioinformatics.
References
- Prathmesh, J., Manohar, K., Ravina, J., Aishwarya, S., Shweta, K., and Honmane, P. On overview- Corona virus and Hanta virus Disease. Asian Journal of Research and Pharmacological Science. 2020; 10(3):178-182.
- Smith, W., and Freedman, DO. Isolation, quarantine, social distancing, and community containment: a pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak. Journal of Travel Medicine. 2020; 13; 27(2),1–4.
- Young, BE., Ong, S., Kalimuddin, S., Low, JG., Tan, SY., Loh, J., et al. (2020). Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA, Mar. 3. https://doi.org/10.1001/jama.2020.3204.
- Michelle, L., Zh, Q., De, D., Qin, X., Warren, L., and Wee, Y. (2020). A tale of two cities: a comparison of Hong Kong and Singapore's early strategies for the Coronavirus Disease 2019 (COVID-19). The Journal of Infection, S0163-4453(20)30439-4. https://doi.org/10.1016/j.jinf.2020.06.058.
- Dawood, A., and Altobje, M. (2020). Precautionary measures are taken by countries to reduce the transmission of the COVID-19. Asian Journal of Advances in Medical Science, 2(2):29-32.
- World Health Organization. (2020). SARS-CoV-2 mink-associated variant strain – Denmark. Nov. 6. https://www.who.int/csr/don/06-november-2020-mink-associated-sars-cov2-denmark/en/.
- Paiman, A. (2020). Leading Quarantines in the Time of COVID-19 Case Raparin-Area Kurdistan Region of Iraq, Rawand ESA. JMIR Preprints, 07/04/2020:19175. https://doi.org/10.2196/preprints.19175.
- Dawood, A., Altobje, M. (2020). Inhibition of N-linked Glycosylation by Tunicamycin May Contribute to The Treatment of SARS-CoV-2. Microbial Pathogenesis, 149:104586. https://doi.org/10.1016/j.micpath.2020.104586.
- Srinivasan, S., Cui, H., Gao, Z., Liu, M.,Lu, S., Mkandawire, W., Narykov, O., Sun, M., and Korkin, D. (2020). Structural Genomics of SARS-CoV-2 Indicates Evolutionary Conserved Functional Regions of Viral Proteins. Viruses, 12, (360). https://doi:10.3390/v12040360.
- Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., et al. (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020: https://doi.org/10.1001/jama.2020.1585.
- Vankadari N, and Wilce JA. Emerging COVID-19 coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emr.Mic.Inf. 2020): Vol.9. https://doi.org/10.1080/22221751.2020.1739565.
- Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020: https://doi.org/10.1001/jama.2020.1585.
- Andersen, G., Rambaut, A., Lipkin, I., Holmes, C., and Garry, F. (2020). The proximal origin of SARS-CoV-2. Nature Medicine, 26, 450–452. https://doi:10.1038/s41591-020-0820-9.
- Shen, Z., Xiao, Y., Kang, L., Ma, W., Shi, L., Zhang, L. et al. (2020). Genomic diversity of SARS-CoV-2 in coronavirus disease 2019 patients. Clinical Infection Disease, ciaa203. https://doi:10.1093/cid/ciaa203.
- Dawood, A. (2020). Mutated COVID-19, May Foretells Mankind in a Great Risk in The Future. New Microbes and new Infections, (35): 100673. https://doi.org/10.1016/j.nmni.2020.100673.
- Fung, T., and Liu, D. (2020). Coronavirus infection, ER stress, apoptosis and innate Immunity. Frontiers in Microbiology, 5(296). https://doi:10.3389/fmicb.2014.00296.
- Manisha, R., Pradnya, K. (2020). Coronavirus Disease: A Review of a New Threat to Public Health. Asian J. Pharm. Res. 2020; 10(3):241-244.
- Wrap D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C-L., Abiona O., Graham B.S., and McLellan S.J. Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. Science, 367(6483):1260-1263. https://doi.org/10.1101/2020.02.11.944462.
- Dawood, A., Alnori, H. (2020). Tunicamycin Anticancer Drug May Reliable to Treat Coronavirus Disease-19. Open Access Macedonian Jjournal of Medical Sciences, 8(T1):129-133. https://doi.org/10.3889/oamjms.2020.4954.
- Wan, Y., Shang, J., Graham, R., Baric, RS., Li, L. (2020). Receptor recognition by a novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. Journal of Virology, 94: (7) e00127-20. https://doi.org/10.1128/JVI.00127-20.
- Cubuk, H., and Ozbil, M. (2020). Comparison of Clinically Approved Molecules on SARS-CoV-2 Drug Target Proteins: A Molecular Docking Study. ChemRxiv, https://doi.org/10.26434/chemrxiv.12090828.v1.
- Dawood A, Altobje M, and Alnori H. Compatibility of the Ligand Binding Sites in the Spike Glycoprotein of COVID-19 with those in the Aminopeptidase and the Caveolins 1, 2 Proteins. Res J Pharm Tech. 2021; 14(9): 4760-4766. doi:10.52711/0974-360X.2021.00828. https://rjptonline.org/AbstractView.aspx?PID=2021-14-9-42.
- World Travel Guide. (2020). Can you travel safely when Coronavirus (COVID-19) is spreading fast? 2020;https://www.worldtravelguide.net/features/feature/can-you-travel-safely-when-coronavirus-covid-19-is-spreading-fast/.
- Hafi, B., Uvais, N., Jafferany, M., Afra, T., and Ramzi, T. (2020). Can COVID-19 virus be transmitted through sex? Dermatologic Therapy, https://doi:10.1111/dth.13679.
- Dawood, A. Transmission of SARS CoV-2 virus through the ocular mucosa worth taking precautions. Vacunas. 22(1):56–57. https://doi.org/10.1016/j.vacun.2020.09.003.
- Mayur S. Jain, Shashikant D. Barhate. Corona viruses are a family of viruses that range from the common cold to MERS corona virus: A Review. Asian J. Res. Pharm. Sci. 2020; 10(3):204-210. 27. Ali A. Dawood. The Russian Vaccine of COVID-19 (Sputnik V) has shown side effects on the Volunteers. Asian Journal of Research in Pharmaceutical Sciences. 2021; 11(3):193-4.
- Ritik S. Jain, Tejas G. Jain, Suraj K. Ishikar. Impact of Covid-19 on Changing Habits and Health Issues of the Public. Asian Journal of Management. 2020;11(4):524-528.
- Enhancement of Antibodies Neutralize Omicron variants in The Presence of Booster Vaccine Doses and Monoclonal Antibodies
Abstract Views :58 |
PDF Views:0
Authors
Affiliations
1 Al-Jameaa, 1st, Mosul., IN
1 Al-Jameaa, 1st, Mosul., IN
Source
Research Journal of Science and Technology, Vol 14, No 2 (2022), Pagination: 95-97Abstract
The Omicron variant is quickly becoming the most common SARS-CoV-2 virus spreading throughout the world. To understand probable loss of protection against Omicron infection, it's critical to identify declines in viral neutralizing activity in serum of convalescent or vaccinated people. Antibodies against Omicron and various variants have been detected by scientists. These antibodies target non-evolving regions of the viral spike protein. A booster dose improves the quality and amount of the humoral immune response, which has been related to better protection against the disease's more severe signs. Vaccines and boosters must be provided promptly around the world to stop the virus from spreading.Keywords
Omicron, SARS-CoV-2, Antibodies, Neutralize, Vaccine.References
- Dejnirattisai W. et al. Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum. medRxiv. 2021; 2012.2010.21267534, https://doi.org/10.1101/2021.12.10.21267534.
- Aggarwal A. et al. SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. medRxiv. 2021; 2012.2014.21267772. https://doi.org/10.1101/2021.12.14.21267772.
- Dawood A, Altobje M, and Alnori H. Compatibility of the Ligand Binding Sites in the Spike Glycoprotein of COVID-19 with those in the Aminopeptidase and the Caveolins 1, 2 Proteins. Res J Pharm Tech. 2021; 14(9): 4760-4766. doi:10.52711/0974-360X.2021.00828.
- Redd A. D. et al. Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals. Preprint at Biorxiv. https://doi.org/10.1101/2021.12.06.471446.
- Dawood A, Altobje M, and Alrassam Z. Molecular Docking of SARS-CoV-2 Nucleocapsid Protein with Angiotensin-Converting Enzyme II. Mikrobio Zhu. 2021; 83(2):82-92. doi: 10.15407/microbiolj83.02.082.
- Planas D. et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nature Med. 201; 27, 917-924. https://doi.org/10.1038/s41591-021-01318-5.
- Dawood A. Increasing the frequency of omicron variant mutations boosts the immune response and may reduce the virus virulence. Microb Path. 2022; 154 (105400). https://doi.org/10.1016/j.micpath.2022.105400.
- Rappazzo G. et al. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science. 2021; 371, 823-829. https://doi.org/10.1126/science.abf4830.
- Jones E. et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Trans Med. 2021; 13, eabf1906, https://doi.org/10.1126/scitranslmed.abf1906.
- Sun S, Gu H, Cao L, Chen Q, Ye Q, and Yang G, et al. Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2. Nat Commun. 2021; 12, 5654.
- Telenti A, Arvin A, Corey L, Corti D, Diamond MS, and Garcia-Sastre A, et al. After the pandemic: perspectives on the future trajectory of COVID-19. Nature. 2021; 596, 495e504.